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Abstract
Background: Fabry disease is an X-linked lysosomal storage disorder due to α-galactosidase A (α-Gal A) deficiency.
Clinical onset of Fabry disease is preceded by significant storage of globotriaosylceramide (Gb3) and related
glycosphingolipids, but the extent of the metabolic progression before symptoms is unknown. Using a newly
recognized effector and marker of Fabry disease, globotriaosylsphingosine (LysoGb3), we aimed to provide a
metabolic picture of classic Fabry disease from the neonatal period to childhood.
Methods: LysoGb3 was assessed at different times in two brothers with classic Fabry disease (genotype c. 370–2
A > G). The firstborn was diagnosed after clinical onset at 11 years of age, whereas the second-born was diagnosed
in the neonatal period. LysoGb3 was measured in dried blood spots by high-sensitive electrospray ionization liquid
chromatography tandem mass spectrometry.
Results: Blood LysoGb3 concentrations were consistent with patients’ age and clinical picture, with lower levels in
the asymptomatic neonate (19.1 ng/ml) and higher levels in the symptomatic child (94.3 ng/ml). In the second-
born, LysoGb3 doubled during the first 5 months of life (37.4 ng/ml), reaching ~40% concentration observed in the
symptomatic period. The neonatal LysoGb3 concentration in classic Fabry disease exceeded that observed in
normal subjects by over 15 times.
Conclusions: A substantial increase of LysoGb3 was documented during the first months of life in classic Fabry
disease, suggesting an early plateau during the pre-symptomatic period. Such a progressive metabolic trend during
the pre-symptomatic period implies the potential definition of a metabolic threshold useful for a preventive
therapeutic approach of classic Fabry disease. Additionally, the consistent increase of LysoGb3 in the neonatal
period in classic Fabry disease suggests LysoGb3 as a useful marker for improving the specificity of newborn
screening for Fabry disease.
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Background
Fabry disease (OMIM 301500) is an X-linked lysosomal
storage disorder due to α-galactosidase A (α-Gal A) defi-
ciency. The enzymatic defect leads to progressive accu-
mulation of globotriaosylceramide (Gb3) and related
glycosphingolipids in the vascular endothelium, particu-
larly in kidney, brain, and heart. Affected males with
complete or near-complete α-Gal A deficiency exhibit
the classic clinical phenotype of Fabry disease with onset
of angiokeratomas, acroparesthesias, hypohidrosis, and
corneal opacities in childhood, followed by renal failure,
cardiac and cerebrovascular disease, and premature
death [1, 2]. A wide spectrum of later-onset variants
have been described in patients with residual α-Gal A
activity, including the “renal variant” and the “cardiac
variant”. Since 2001, an effective enzyme replacement
therapy (ERT) is available [3].
Recently, globotriaosylsphingosine (LysoGb3), a deacy-
lated form of Gb3, was identified as a new pathogenetic
effector and hallmark of Fabry disease, representing a
promising non-invasive marker for monitoring the dis-
ease [4]. Differently from plasma Gb3, plasma LysoGb3
was shown to be dramatically increased in both males
with classic Fabry disease and symptomatic females
heterozygous for mutations in the α-galactosidase A
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gene [5]. Since the clinical phenotype of Fabry disease is
invariably preceded by earlier progressive lysosomal
storage of glycosphingolipids [6], the analysis of periph-
eral LysoGb3 may allow investigation of patients’ meta-
bolic phenotype even in the pre-symptomatic period.
Here we report LysoGb3 analysis in two brothers with
classic Fabry disease with 14 years age difference, giving a
picture of metabolic phenotype and natural progression of
Fabry disease from the neonatal period to childhood.
Methods
The genealogy of the two brothers with classic Fabry
disease is depicted in Fig. 1 (panel a). The clinical course
of the first-born brother was uneventful until 11 years of
age, when persistent acroparesthesias and burning pain
were reported. A definite diagnosis of classic Fabry
disease was made on the basis of biochemical and
molecular data (α-Gal A activity = 0.2 nmol/h/ml,
normal value >2 nmol/h/ml; genotype c. 370–2 A > G).
A basal LysoGb3 analysis on dried blood spot was obtained
just before starting ERT. Based on familiar anamnesis, the
second-born brother was diagnosed with classic Fabry
disease in the neonatal period (α-Gal A activity = 0.7 nmol/
h/ml; normal value >2 nmol/h/ml; genotype c. 370–2 A >
G), undergoing LysoGb3 analysis at 2 days of life. A further
LysoGb3 measurement was performed at 5 months.
LysoGb3 was measured in dried blood spot samples by
high-sensitive electrospray ionization liquid chromatog-
raphy tandem mass spectrometry (ESI LC-MS/MS). A 7-
point serum calibrator for lysoGb3 quantification (cover-
ing the analytic range from 0–120 ng/mL; lower limit of
quantification: 1.5 ng/mL) and three calibrator levels (3,
30 and 100 ng/mL) for quality control were used
(ARCHIMED Life Science GmbH, Vienna, Austria;
www.archimedlife.com).
Results
Blood LysoGb3 concentrations were consistent with pa-
tients’ age and clinical picture, with lower levels in the
asymptomatic neonate and higher levels in the symptom-
atic child. LysoGb3 in the second-born doubled during
the first 5 months of life, reaching ~40% concentration
observed in the symptomatic period (Fig. 1, panel b). The
comparison of LysoGb3 concentrations in the two broth-
ers with classic Fabry disease revealed its 5-fold increase
from the neonatal period to childhood (Fig. 1, panel b).
The neonatal LysoGb3 concentration in classic Fabry dis-
ease, moreover, exceeds that observed in normal subjects
by over 15 times (Fig. 1, panel b).
Discussion
In 2006, we were the first to demonstrate a high incidence
of later-onset Fabry disease as opposed to classic Fabry dis-
ease [7], subsequently confirmed in other studies [8, 9]. A
variable symptom-free interval characterizes all forms of
Fabry disease, and clinical phenotype is preceded and sus-
tained by progressive glycosphingolipids storage [3]. In re-
cent years, little was known about pre-symptomatic Fabry
disease, especially since invasive procedures were invari-
ably required for any pathological assessment. For in-
stance, serial renal biopsies showed that Gb3 storage even
precedes microalbuminuria in patients with Fabry disease
Fig. 1 a, Familial pedigree of two brothers (“x” and “y”) with classic Fabry disease (details in text). Patient “0” was diagnosed with end-stage renal
disease due to classic Fabry disease at 35 years of age. b, Globotriaosylsphingosine (LysoGb3) assessed on dried blood spot (DBS) in two brothers
(“x” and “y”) at different metabolic and clinical stages of classic Fabry disease
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[10]. Recently, podocyturia was identified as an early useful
marker of renal damage in Fabry disease [11, 12].
LysoGb3 is a new, easily measurable marker and
pathogenic effector of Fabry disease [4]. Smid and col-
leagues recently described the superior diagnostic utility
of lysoGb3 compared to Gb3 to discern non-classical,
uncertain or patients having no Fabry disease [13].
LysoGb3 can be measured in plasma or in dried blood
spots [14], representing a potential new avenue to the
comprehension of metabolic progression of Fabry disease
from the pre-symptomatic to the symptomatic period.
This potential of LysoGb3, indeed, may be useful for mon-
itoring patients detected through newborn- or selective-
screening for Fabry disease, improving the sensitivity of
the clinical approach to prevent irreversible organ damage.
In this study, the comparison of LysoGb3 in two
brothers with complete α-Gal A deficiency describes the
extent of glycosphingolipids storage during childhood in
classic Fabry disease and its relationship with clinical
onset. The early and consistent increase of LysoGb3
observed in the neonatal period in classic Fabry disease
is consistent with its fetal storage [6], making LysoGb3 a
potential useful tool for improving the specificity of
newborn screening for Fabry disease. Moreover, a sub-
stantial increase of LysoGb3 was documented during
infancy in classic Fabry disease, suggesting an early plat-
eau during the pre-symptomatic period. The observation
of such a progressive metabolic trend in pre-symptomatic
and early-symptomatic patients with classic Fabry disease
implies the potential definition of a metabolic threshold
(i.e. a LysoGb3 cut-off) useful for addressing an early
preventive therapeutic approach to Fabry disease.
Conclusions
These observations suggest a new nosological classifica-
tion of Fabry disease, based on the metabolic phenotype
instead of the clinical phenotype. Early screening for
Fabry disease and longitudinal pre-symptomatic non-
invasive biochemical monitoring are essential to this
definition. Anticipating clinical attention on patients’
metabolic phenotype may represent a new frontier for the
optimization of medical management of Fabry disease.
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